Invitrocue Limited (ASX: IVQ) is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models derived from liver and tumour tissues. Headquartered in Singapore and with operations in Australia, Germany, Hong Kong and China. Invitrocue’s Onco-PDO test enables a personalised and patient-specific approach to recreating cancer cells (organoids) that can be cultured in laboratories for testing against a panel of cancer drugs to support clinical, economical and lifestyle decision making. Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrouce’s products have been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.